The Effects of Canagliflozin on Heart Failure and Cardiovascular Death by Baseline Participant Characteristics: Analysis of the CREDENCE Trial. Diabetes, obesity & metabolism Arnott, C., Li, J., Cannon, C. P., de Zeeuw, D., Neuen, B. L., Heerspink, H. J., Charytan, D. M., Agarwal, A., Huffman, M. D., Figtree, G. A., Bakris, G., Chang, T. I., Feng, K., Rosenthal, N., Zinman, B., Jardine, M. J., Perkovic, V., Neal, B., Mahaffey, K. W. 2021


Heart failure is prevalent in those with type 2 diabetes and chronic kidney disease and is associated with significant mortality and morbidity. In the CREDENCE trial canagliflozin reduced the risk of hospitalization for heart failure (HHF) or cardiovascular (CV) death by 31%. In this current analysis we sought to determine whether the effect of canagliflozin on HHF/CV death differed in subgroups defined by key baseline participant characteristics. Cox regression models were used to estimate hazard ratios and 95% confidence intervals. Canagliflozin was associated with a reduction in the relative risk of HHF/CV death regardless of age, sex, history of HF or CV disease, and the use of loop diuretics or GLP1 receptor agonists (all pinteraction >0.114). The absolute benefit of canagliflozin was greater in those at highest baseline risk, such as those with CV disease (50 fewer events/1000 patients treated over 2.5years versus 20 fewer events in those without CV disease) or advanced kidney disease (eGFR 30-45 ml/min/1.73m2 : 61 events prevented/1000 patients treated over 2.5years versus 23 events in eGFR 60-90 ml/min/1.73m2 ). Canagliflozin consistently reduces the proportional risk of HHF/CV death across a broad range of subgroups with greater absolute benefits in those at highest baseline risk. This article is protected by copyright. All rights reserved.

View details for DOI 10.1111/dom.14386

View details for PubMedID 33769679